PDF(Pubmed)
Abstract：
Intravenous iron replacement therapy is a common treatment for iron deficiency. Commonly used agents in this treatment include ferric carboxymaltose, ferric derisomaltose, and saccharated ferric oxide (SFO). These drugs are known to elevate fibroblast growth factor 23 levels, resulting in hypophosphatemia, but in past reports, hypophosphatemia attributable to SFO treatment has been associated mainly with prolonged administration over several weeks. The present study details our experience of a case of moderate hypophosphatemia (<2 mg/dL) in a 22-year-old woman who had no specific history of hypophosphatemia during the first 5 days of SFO treatment, and showed an increase in intact fibroblast growth factor 23 levels within the first week of treatment. Cases of hypophosphatemia have been reported as occurring as early as 1 week after the start of SFO administration in the Japanese Adverse Drug Event Report database. These cases, along with our case, underline the need for awareness of the possibility of hypophosphatemia from the early stage of SFO administration, regardless of the patient\'s age or dosage, as well as the need to monitor patients to prevent complications.
摘要：
静脉铁替代疗法是铁缺乏的常用治疗方法。这种治疗中常用的药物包括羧基麦芽糖铁，地异麦芽糖铁,和糖化氧化铁(SFO)。已知这些药物可以提高成纤维细胞生长因子23的水平，导致低磷酸盐血症，但在过去的报道中,SFO治疗引起的低磷酸盐血症主要与数周内的长期给药有关.本研究详述了我们对一名22岁女性的中度低磷酸盐血症（<2mg/dL）病例的经验，该女性在SFO治疗的前5天没有特定的低磷酸盐血症史，并在治疗的第一周内显示完整的成纤维细胞生长因子23水平增加。在日本不良药物事件报告数据库中，据报道，低磷酸盐血症病例最早发生在SFO开始后1周。这些案件,连同我们的案子,强调需要从SFO管理的早期阶段就意识到低磷酸盐血症的可能性，无论患者的年龄或剂量，以及需要监测患者以防止并发症。
